[HTML][HTML] Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure
P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
P Armand, MA Shipp, V Ribrag, JM Michot, PL Zinzani, J Kuruvilla, ES Snyder, AD Ricart…
Journal of Clinical Oncology, 2016•ncbi.nlm.nih.govProgrammed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin
Lymphoma After Brentuximab Vedotin Failure - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin
Oncol PMC5791838 Other Formats PDF (835K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Lymphoma After Brentuximab Vedotin Failure - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin
Oncol PMC5791838 Other Formats PDF (835K) Actions Cite Collections Share Permalink Copy
RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal List J …
Abstract
Purpose
Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible vulnerability to PD-1 blockade. The phase Ib study KEYNOTE-013 (NCT01953692
ncbi.nlm.nih.gov